• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Dupixent

AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3

By Pallavi Madhiraju on June 21, 2026   Pharma & Biotech  

AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3

AbbVie could pay a substantial premium for Apogee Therapeutics and its long-acting eczema antibody, but the reported deal depends on Phase 3 success and differentiation from established immunology drugs.

GSK’s Exdensur wins FDA nod for severe asthma: Can twice-yearly dosing reset the biologics playbook?

By Pallavi Madhiraju on December 17, 2025   Pharma & Biotech  

GSK’s Exdensur wins FDA nod for severe asthma: Can twice-yearly dosing reset the biologics playbook?

GSK’s Exdensur has been approved by the FDA as the first biannual biologic for severe asthma. Find out what this means for patients, payers, and rivals.

Recent Posts

  • Why Premier Biotech’s NexScreen and TransMed acquisitions could reshape rapid drug testing
  • Chai Discovery tests a new commercial route for AI-designed biologics through Lilly TuneLab
  • Why Veraxa Biotech stock fell 23% after its BiTAC-ADC proof-of-concept data
  • Greenstone Biosciences and Intel chase faster drug discovery as regulators back human-relevant models
  • Why AngioDynamics stock investors should watch NanoKnife’s move into benign prostate disease
  • Canada’s healthcare market faces a turning point as Alberta prepares dual-practice surgery launch
  • AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3
  • Memo Therapeutics advances potravitug as the race for the first BK virus therapy intensifies
  • CureGene targets clopidogrel variability as evategrel begins a critical United States study
  • GSK and Spero win Utebzi approval after an earlier FDA rejection and new Phase 3 trial
  • Can uniQure turn the FDA’s AMT-130 reversal into a Huntington’s disease approval?
  • Replicate Bioscience wins Gates Foundation support for an ambitious TB vaccine strategy
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes